Effects of Pegaptanib Sodium on Retinal Function in Isolated Perfused Vertebrate Retina

REFERENCES

• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al.VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816.
   PubMed Web of Science ®Google Scholar
• VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508–1521.
   PubMed Web of Science ®Google Scholar
• Ishida S, Usui T, Yamashiro K, et al.VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483–489.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Hata Y, Yoshikawa H, et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159–167.
   PubMed Web of Science ®Google Scholar
• Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929–1934.
   PubMed Web of Science ®Google Scholar
• Pauleikhoff D. Neovascular age-related macular degeneration: Natural history and treatment outcomes. Retina 2005;25:1065–1084.
   PubMed Web of Science ®Google Scholar
• Lee JH, Canny MD, De Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A 2005;102:18902–18907.
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123–132.
   PubMed Web of Science ®Google Scholar
• Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167:1451–1459.
   PubMed Web of Science ®Google Scholar
• Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53–67.
   PubMed Web of Science ®Google Scholar
• Kilic U, Kilic E, Järve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERI-1/2 and Akt pathways. J Neurosci 2006;26:12439–12446.
   PubMed Web of Science ®Google Scholar
• Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: Promises and potential problems. JAMA 2005;293:1509–1513.
   PubMed Web of Science ®Google Scholar
• Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:11695.e1–e15.
   Google Scholar
• Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: Third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008;92:1606–1611.
   PubMed Web of Science ®Google Scholar
• Lüke M, Weiergräber M, Brand C, et al. The isolated perfused bovine retina—A sensitive tool for pharmacological research on retinal function. Brain Res Brain Res Protoc 2005;16:27–36.
   PubMedGoogle Scholar
• Hanawa I, Tateishi T. The effect of aspartate on the electroretinogram of the vertebrate retina. Experientia 1970;26:1311–1312.
   Google Scholar
• Lüke C, Walter P, Bartz-Schmidt KU, et al.Effects of antiviral agents on retinal function in vertebrate retina. In: K Green (Ed.). Advances in Ocular Toxicology. New York: Plenum Press, 1997; pp. 107–112.
   Google Scholar
• Walter P, Lüke C, Sickel W. Antibiotics and light responses in superfused bovine retina. Cell Moll Neurobiol 1999;19:87–92.
   Google Scholar
• Foy JW, Rittenhouse K, Modi M, et al. Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit. J Ocul Pharmacol Ther 2007;23:452–466.
   PubMed Web of Science ®Google Scholar
• Lipski A, Bornfeld N, Jurklies B. Multifocal electroretinography in patients with exudative AMD and intravitreal treatment with pegaptanib sodium. Retina 2007;27:864–872.
   PubMed Web of Science ®Google Scholar
• Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560–H576.
   PubMed Web of Science ®Google Scholar
• Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495–511.
   PubMed Web of Science ®Google Scholar
• Lüke M, Warga M, Ziemssen F, et al.Tuebingen Bevacizumab Study Group. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006;90:1178–1182.
   PubMed Web of Science ®Google Scholar